EUVIMEDEUVIMED entdecken
Vergleichsstudie

Head-to-head comparison of [18F]AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors

Xiao Jin, Qing Xie, Xiangxiang Ding, Boqi Yu, Yan Zhang, Xiaofan Su, Chunhui Yuan, Ming Lu, Zhi Yang, Jiangyuan Yu

European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8651-8660

DOI: 10.1007/s00259-026-08176-8 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 21.09.2026. Verfasst von Xiao Jin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharm…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Neuroendocrine Tumors, Magnetic Resonance Imaging, Organometallic Compounds. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Capital Health Research and Development Special Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To compare [18F] AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors (NETs). METHODS: Forty-one patients with biopsy-proven NETs were enrolled and underwent [68Ga]Ga-DOTA-TATE PET/CT and [18F] AlF-NOTA-JR11 PET/MR. Physiological organ uptake, lesion number, maximum standardized uptake value (SUVmax) and tumor-to-background ratio (TBR) were compared between the two examinations. RESULTS: [18F] AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT depicted 924 and 580 lesions, respectively (p < 0.001).These included 754 and 405 liver metastases(p < 0.001), as well as 29 and 25 primary tumors (p = 0.125), respectively. The 405 liver metastases detected by both examinations were significantly larger than the 349 lesions detected only by [18F]AlF-NOTA-JR11 [median diameter, 14.00 mm (Q1, Q3: 10.00, 21,00) vs. 6.00 mm (Q1, Q3: 5.00, 9.00); p < 0.001]. No significant differences were found for the detection of lymph node metastases (p = 1.000) or bone metastases (p = 0.188). In the patient-based comparison, 76% of patients (31/41) had more lesions detected by [18F]AlF-NOTA-JR11 PET/MR than by [68Ga]Ga-DOTA-TATE PET/CT. Lesion SUVmax for [18F]AlF-NOTA-JR11 was significantly lower than that for [68Ga]Ga-DOTA-TATE in primary tumors (p = 0.002), liver metastases (p = 0.017) and bone metastases (p = 0.008), whereas no significant difference was observed in lymph node metastases (p = 0.144). [18F]AlF-NOTA-JR11 PET/MR showed higher TBR than [68Ga]Ga-DOTA-TATE PET/CT in primary tumors (p = 0.014), lymph node metastases (p = 0.034) and liver metastases (p < 0.001), with no significant difference in bone metastases(p = 0.343). CONCLUSION: [18F]AlF-NOTA-JR11 PET/MR shows lower background uptake and higher TBR for primary tumors, lymph node metastases and liver metastases. It also detected more liver metastases than [68Ga]Ga-DOTA-TATE PET/CT. These findings provide valuable evidence supporting the clinical use of [18F]AlF-NOTA-JR11 PET/MR in patients with NETs. TRIAL REGISTRATION NUMBER: 2020KT15 DATE OF REGISTRATION: 30/03/2020.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyNeuroendocrine TumorsMagnetic Resonance ImagingOrganometallic CompoundsHeterocyclic CompoundsHumansFemaleMaleMiddle AgedAgedAdultFluorine RadioisotopesHeterocyclic Compounds, 1-RingAged, 80 and over

Stichwörter der Autor:innen

Neuroendocrine tumorPET/MRSSTR antagonist[18F]AlF-NOTA-JR11

Substanzen

Organometallic CompoundsHeterocyclic CompoundsFluorine Radioisotopes1,4,7-triazacyclononane-N,N',N''-triacetic acidHeterocyclic Compounds, 1-Ring

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of N…
  • Beijing United Imaging Healthcare Technology Development Co., Ltd, Beijing, China.
  • Department of General Surgery, Peking University Third Hospital, Beijing, 100191, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.

Förderung

  • Capital Health Research and Development Special Project

Zitieren

APA

Jin, X., Xie, Q., Ding, X., Yu, B., Zhang, Y., Su, X., Yuan, C., Lu, M., Yang, Z., & Yu, J. (2026). Head-to-head comparison of [18F]AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8651-8660. https://doi.org/10.1007/s00259-026-08176-8

Vancouver

Jin X, Xie Q, Ding X, Yu B, Zhang Y, Su X, et al. Head-to-head comparison of [18F]AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8651-8660. doi:10.1007/s00259-026-08176-8

BibTeX
@article{Jin2026,
  author = {Jin, Xiao and Xie, Qing and Ding, Xiangxiang and Yu, Boqi and Zhang, Yan and Su, Xiaofan and Yuan, Chunhui and Lu, Ming and Yang, Zhi and Yu, Jiangyuan},
  title = {Head-to-head comparison of [18F]AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {13},
  pages = {8651--8660},
  doi = {10.1007/s00259-026-08176-8}
}
Kostenlos starten →